Story thread · 4 reports / 3 sources
STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
statnews.com · 3h · first report
How the coverage leans
Across 3 sources · syndicated copies counted once
The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
The coverage
- How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
investors.com · 1h
- Alkermes stock jumps on positive ADHD drug trial results
investing.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.